Development and validation of LC–QTOF–MS/MS method for the identification and determination of low levels of a genotoxic impurity, 4,6‐dichloro‐5‐nitro‐2‐(propylthio)pyrimidine in ticagrelor API
- 12 January 2022
- journal article
- research article
- Published by Wiley in Biomedical Chromatography
- Vol. 36 (4) , e5336
Abstract
The foremost objective of the present study was to develop and validate a new LC–QTOF–MS/MS method for the identification and quantitative determination of 4,6‐dichloro‐5‐nitro‐2‐(propylthio)pyrimidine (DPP) genotoxic impurity through the derivatization process in ticagrelor active pharmaceutical ingredient (API). Owing to the low response of DPP at the specification level, DPP was converted to 4,6‐dibenzylamino‐5‐nitro‐2‐(propylthio)pyrimidine (DPP derivative) by addition of benzyl amine, then analyzed using mass spectrometry with a time‐of‐flight analyzer, and good separation was accomplished under the experimental conditions described. The effective separation of DPP derivative was achieved using an Acquity UPLC BEH C18 reverse‐phase column (100 × 4.6 mm × 1.7 μm) with an isocratic program with mobile phase A as 0.1% formic acid in milli Q water and mobile phase B as acetonitrile in the ratio of 20:80 v/v. The flow rate was maintained as 0.4 ml/min, the injection volume was 2 μl, the autosampler temperature was 5°C, the column oven temperature was ambient and the run time was 6.0 min. The diluent used was 0.2% benzyl amine in water and acetonitrile in the ratio of 30:70 v/v. The retention time of the DPP derivative was 2.87 min. The limit of detection and limit of quantification were 0.03 and 0.08 ppm, respectively. The DPP derivative was linear from 1.68 to 12.78 ppm with R2 of 0.9958. Thus, the developed method is valid for the identification and quantitative determination of DPP derivative in ticagrelor API.Keywords
This publication has 19 references indexed in Scilit:
- Reversal of the platelet inhibitory effect of the P2Y12 inhibitors clopidogrel, prasugrel, and ticagrelor in vitro: a new approach to an old issueClinical Research in Cardiology, 2017
- HPLC method for simultaneous analysis of ticagrelor and its organic impurities and identification of two major photodegradation productsEuropean Journal of Pharmaceutical Sciences, 2017
- Principles and procedures for implementation of ICH M7 recommended (Q)SAR analysesRegulatory Toxicology and Pharmacology, 2016
- Four process-related potential new impurities in ticagrelor: Identification, isolation, characterization using HPLC, LC/ESI–MSn, NMR and their synthesisJournal of Pharmaceutical and Biomedical Analysis, 2016
- An efficient and safe process for the preparation of ticagrelor, a platelet aggregation inhibitor via resin-NO2 catalyzed formation of triazole ringSpringerPlus, 2015
- Ticagrelor: A Review of Its Use in Adults with Acute Coronary SyndromesAmerican Journal of Cardiovascular Drugs, 2015
- Die International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH)2014
- Ticagrelor: Oral Reversible P2Y12 Receptor Antagonist for the Management of Acute Coronary SyndromesClinical Therapeutics, 2012
- Strategies for the identification, control and determination of genotoxic impurities in drug substances: A pharmaceutical industry perspectiveJournal of Pharmaceutical and Biomedical Analysis, 2011
- Regulation of genotoxic and carcinogenic impurities in drug substances and productsTrAC Trends in Analytical Chemistry, 2006